Kidney Week

Abstract: SA-PO0629

Efficacy and Safety of Long-Term Telitacicept Treatment in Patients with Primary IgAN: A Report of 25 Cases

Session Information

• Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - Other
  October 24, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

• Pei, Juan, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China

Juan Pei, MD

• Li, Yinan, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China

Yinan Li

• Shao, Leping, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China

Leping Shao, MD, PhD

Background

Immunoglobulin A nephropathy (IgAN), a major global cause of end-stage renal disease, is driven by the production of pathogenic galactose-deficient IgA1 (Gd-IgA1). Targeting the upstream drivers of this production remains a therapeutic goal. Telitacicept is a novel fusion protein that simultaneously neutralizes two critical B-cell survival factors, BLyS and APRIL, thereby impacting the secretion of autoantibodies by plasma cells. The purpose of this study was to evaluate the efficacy and safety of long- term telitacicept in adults with primary IgA nephropathy.

Methods

This was a single-center retrospective study. Biopsy-proven IgAN patients with 24-hour proteinuria greater than 0.5g/d who received telitacicept between November 2022 and December 2024 were recruited. Patients were followed for 6-12 months.

Results

A total of 25 patients were followed up to 6 months, with 11 completing the 12-month assessment. The median 24-hour proteinuria decreased significantly from 2291 g/day (IQR, 1222-5006) at baseline to 669 mg/day (IQR, 479-1674) at month 3 (P < 0.001), and further to 479 mg/day (IQR, 260-1128) at month 6 (P < 0.001). At 12 months, the 24-hour proteinuria was 720 mg/day (IQR, 349-876) (P < 0.001 vs. baseline), representing a reduction of 72.59% (95% CI: 54.26–89.99, p = 0.003). Mean eGFR was 82.19±30.40 mL/min/1.73m² at baseline, transiently decreased to 74.92±31.26 mL/min/1.73m² (P = 0.020), returned to a comparable level at month 6 (81.19±24.83 mL/min/1.73m², P = 0.126), and was 97.38±22.54 mL/min/1.73m² at month 12 (P = 0.598). No serious adverse events were reported.

Conclusion

In this real-world study, telitacicept combined with conventional therapy demonstrated rapid onset of efficacy, sustained long-term effectiveness, and a favorable safety profile in patients with IgA nephropathy.

Acknowledgment

We are grateful to all participants, the doctors, and nurses of the Nephrology department for their efforts and contributions to this research.